Pharma

Your Article Summary

See Latest Articles

Abbotts XIENCE V Superior to TAXUS in Key Safety and Efficacy Measures in SPIRIT IV Trial
Abbott, 09/24/09

Late–breaking data from the SPIRIT IV trial demonstrated that Abbott's market–leading XIENCE V Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure and target lesion revascularization compared to the TAXUS Express Paclitaxel–Eluting Coronary Stent System at one year. With 3,690 patients, the SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/09/09

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Trials, 12/09/09

Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial
The Lancet - Early Online Publication, 12/09/09

 See all of Drug Trials